

Summary of NICE Guidelines

Title	Peritoneal dialysis in the treatment of stage 5 chronic kidney disease
NICE Reference	CG125
Date of Review:	July 2018
Date of Publication	July 2011
Summary of Guidance (Max 250 words)	<p>Individuals with stage 5 CKD require renal replacement therapy either haemodialysis or peritoneal dialysis.</p> <p>The evidence reviewed suggests that there is no significant difference in outcome for the majority of patients choosing either available modality.</p> <p>Exceptions: Peritoneal dialysis is the first choice in the following groups: children 2 years and under; patients with residual renal function; adults without significant associated co-morbidities.</p> <p>Patients should be supported to make informed decisions about renal replacement therapy, specifically peritoneal dialysis. Balanced and accurate information should be provided about all modalities. The patient's personal circumstances and opinions should be taken into account.</p> <p>Where peritoneal dialysis is selected, the dialysis modality should not be switched in anticipation of complications. Risk factors should be monitored and all aspects of care discussed with patients/carers. Wishes of the patient should be respected and switching considered if requested.</p>
Impact on Lab (See below)	<input checked="" type="checkbox"/> None
Lab professionals to be made aware	Not applicable
Please detail the impact of this guideline (Max 150 words)	CG125 gives guidance for helping the patient choose between haemodialysis and peritoneal dialysis. It does not issue guidance on laboratory testing.

Impact on Lab

- None:** This NICE guideline has no impact on the provision of laboratory services
- Moderate:** This NICE guideline has information that is of relevance to our pathology service and may require review of our current service provision.
- Important:** This NICE guideline is of direct relevance to our pathology service and will have a direct impact on one or more of the services that we currently offer.

Written by: Dr Elizabeth Fox
Reviewed by: Professor Roy Sherwood